Occuity

19/12/2025

Today is the final day of our Republic crowdfunding campaign, so we thought we'd highlight what we said at the beginning & give you five simple reasons why we believe you should invest in Occuity:

- We’re developing technology that can genuinely change lives, using the eye as a window to the health of the body
- We’ve built a patented, non-contact optical platform that underpins multiple current & future devices
- We have an experienced leadership team with deep expertise in optics, engineering & MedTech
- We’re already generating revenue with the PM1, with major growth ahead through the AX1 & beyond
- We’re not a single-product company, but a scalable platform business with a clear roadmap into Oculomics, diabetes and systemic disease screening

If you’ve been watching the campaign and weighing it up, this really is your last chance to join us before the round closes and we move towards our next phase of growth.

Thanks again to everyone who has supported Occuity so far.

18/12/2025

We’re proud to share that Occuity has been featured in Ingenia magazine, the oyal Academy of Engineering’s , quarterly publication showcasing inspiring engineering stories from across the UK.

Ingenia highlights innovative technologies that are shaping the future, and we’re delighted that our work using the eye as a window into wider health has been chosen as an example of how engineering can open up new possibilities in healthcare.

Being featured in such a respected and prestigious publication is a real endorsement of the originality and potential of Occuity’s technology, and we’re pleased to see our approach recognised alongside other groundbreaking engineering innovations.

You can read the full article here: https://zurl.co/YQsAC

16/12/2025

We often say that Occuity is best understood in person.

Our technology platform is powerful, but it naturally raises questions. Seeing it being developed, meeting the team building it, and understanding how everything fits together makes a real difference. That’s why we regularly welcome potential investors to our HQ in Reading to show them first-hand what we’re building and how their investment is being put to work.

In this short video, Richard Kadri-Langford, our Head of Marketing recorded a simple walkthrough of our offices while our CEO, Dr. Dan Daly, talks through who we are, what we do, and how the team operates day to day. It was filmed in a single take to give an authentic, unfiltered view of Occuity as it really is.

As our crowdfunding campaign enters its final days, this gives a real sense of the people, culture and ambition behind the PM1, AX1 and our wider Oculomics platform.

https://zurl.co/hcpqQ

15/12/2025

Over the weekend we passed our £1.1 million target on Republic and welcomed our 300th investor into the Occuity community. Thank you to everyone who has supported the campaign so far.

Hitting our target triggered the official 7 day countdown. This means the round will officially close at 12midnight on Friday 19th December. Once this window closes, the round will end.

If you’ve been following our progress and are considering joining us, now is the moment. With momentum building, major milestones achieved in the lab, and strong interest in our PM1, AX1 and Oculomics roadmap, we believe the future for Occuity has never looked more exciting. As the next round is very likely to be an institutional Series A raise, this will be your last chance to invest in Occuity.

Five days to go. Don’t miss your chance to be part of what comes next.
https://zurl.co/ieqmb

10/12/2025

We passed £1million in our current raise on Republic at the start of the week!

More than 280 investors have now joined us on our mission to transform disease screening and diagnostics using the eye as a window to the health of the body.

Reaching £1 million is a powerful validation of our technology, our team and confidence in our long-term Oculomics strategy. It reflects the growing belief that handheld, non-contact optical devices like the PM1 and AX1 can reshape global healthcare — and that Occuity is the company to deliver that change.

We’re getting closer to our £1.1million target and the campaign will be closing soon.

03/12/2025

Last week, our team achieved a major milestone: a world-first in vivo retinal imaging result using brand-new, non-invasive optical methods developed in our Reading labs.

This breakthrough allows us to distinguish different molecules in the retina in vivo with unprecedented precision — a step that could reshape early detection of both ocular and systemic disease. It’s a huge moment for our Future Leaders Fellowship programme and a powerful validation of the technology we’re building.

(It's frustrating that we cant share more than this, but our team are currently working on patent applications.)

👉 Join us tonight for a webinar, where our Head of Marketing, Richard Kadri-Langford will host a panel discussion with our Senior Leadership team.

If you’re interested in the future of eye-based diagnostics, early disease detection, or investing in high-impact MedTech, this is one you won’t want to miss.

🔗 Register here: https://zurl.co/Qb4ML

Unprecedented In Vivo Retinal Imaging Achieved in Occuity’s Reading Labs

27/11/2025

Have you heard about Occuity and want to understand more about what we do - and where we’re headed? Join us for a special live Q&A Webinar with the leadership team.

This is your chance to explore our technology, ask the questions that matter to you, and understand how we plan to bring our vision to life.

We’ll talk about:
• How our optical platform works
• The products we’re launching now (like the AX1)
• Our long-term ambitions — including diabetes and Alzheimer’s screening
• What investing in Occuity means

Whether you’re already interested, curious, or just looking to learn — we’d love to have you with us.

👉 Learn more and register: https://zurl.co/Wp0gs

See you there — and bring your questions!

We’re excited to invite you to a very special webinar on Wednesday 3rd December 8pm Rather than delivering another standard presentation, we wanted to do something different.

25/11/2025

Last week, our CEO Dan Daly and CCO Mark Jenkins joined Jonathan Roy on the UK Investor Magazine Podcast for a deep dive into Occuity’s mission, technology and progress.

It’s a really insightful conversation covering:

• How we’re using the eye as a window into the health of the body
• The journey from founding Occuity in 2019 to launching our first devices
• The growing global need for non-invasive screening tools
• Our work in myopia management, glaucoma, diabetes and Alzheimer’s
• The vision behind our optical technology platform

If you’re interested in where the future of eye-based health screening is heading, this episode is well worth a listen.

🎧 Listen here:
👉 https://zurl.co/rcxnP

If you have any questions or want to know more about what we’re building, feel free to get in touch.

19/11/2025

It's been another fun day of filming today at Occuity. The day started with a (snow) flurry of activity as we’ve had a creative team from Renishaw in today filming a case study on how we’re using their ATOM™ encoder within our optical technology platform. It’s always exciting when world-leading engineering companies want to showcase how their components help power our devices.

This follows a previous feature we filmed with Onshape, where we gave a behind-the-scenes look at how our engineering team designs and builds the technology that underpins our growing product range. If you missed it, you can watch that video here:
🔗 https://zurl.co/UEowW

For us, it’s further validation that the work happening at Occuity is genuinely cutting-edge — the kind of engineering innovation that attracts interest from some of the biggest names in the industry.

📣 Shareholders and supporters — keep an eye out for the Renishaw case study when it goes live. It’s a great insight into how our tech works behind the scenes.

And if you want to learn more about our vision or take part in our investment round on Republic, you can find the details here:
🔗 https://zurl.co/aq1hh

⚠️ Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 minutes to learn more:
https://zurl.co/n9mBP

06/11/2025

Our Republic Europe crowdfunding round is now live. Secure your priority access, log in now and invest.
👉 Invest here: https://zurl.co/LFmHF

Not registered yet? Do not worry, you can still take part. Simply visit the page below to learn more about our mission, our technology and our plans for growth, and you will be able to invest from as little as £30.

At Occuity, we are working to make Oculomics a practical reality, using the eye as a window into the health of the body. It is an exciting time for the business and we are delighted to now open this next phase of our journey.

Thank you for your early support. It genuinely means a great deal to our team.

Do not invest unless you are prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 minutes to learn more: https://zurl.co/BumkP

05/11/2025

What if a simple, pain-free scan of the eye could help detect and monitor diseases like glaucoma, myopia, diabetes and even Alzheimer’s?

At Occuity, we are building the technology that could make this possible.

Our CEO and Co-Founder, Dan Daly, explains in our new campaign video five reasons why now is the perfect time to invest in Occuity:

👁️ We are using the eye as a window into the health of the body, unlocking earlier, easier and more accessible diagnostics
🔬 Our patented optical platform is already proven and protected, with 15 patents filed
🧑🔬 We have a highly experienced team with award-winning engineers and scientists
📈 We are already generating revenue through our first commercial device and a global distribution network
🚀 We have a clear roadmap, with each device strengthening our platform on the journey toward non-invasive glucose monitoring

This is not a concept. This is a British MedTech company with commercial traction and global ambition.

🎥 Watch the video and learn more about the investment opportunity:
https://zurl.co/hzP73

Invest from as little as £30.

Risk Warning:
Do not invest unless you are prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 minutes to learn more: https://zurl.co/nfcej

31/10/2025

⏳ Why Priority Access matters: It allows you to maintain your shareholding, increase your position, or join the round before allocations fill. Once public, allocation is not guaranteed. Pre-register now: https://zurl.co/pHHrO

Don't invest unless you're prepared to lose all the money you invest.
This is a high-risk investment and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more: https://zurl.co/8pm6Q